Research progress on direct-acting antivirals usage for HCV mono-infection and HCV/HIV co-infection
-
摘要: 在过去几年中,抗丙型肝炎病毒(hepatitis C virus,HCV)治疗药物的研发取得了突破性进展。大量基础和临床研究证实,针对病毒蛋白的直接抗病毒药物(direct-acting antivirals,DAAs)能有效治疗HCV感染,获得高达90%以上的持续病毒应答(sustained viral response,SVR)。然而,由于诸多因素的影响,HCV合并人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染的患者尚未得到有效的抗HCV治疗。在此将重点简述了DAAs的分类、作用机制及其临床试验效果;此外,还介绍了宿主靶向药物(host-targeting agents,HTAs)的研发情况,以及DAAs在HCV合并HIV患者中的临床应用进展。Abstract: In the past several years, research on the development of new drugs for treatment of hepatitis C virus infection has made a breakthrough. A number of basic and clinical studies have proven that direct-acting antivirals (DAAs) that target specific viral proteins are highly effective in treating HCV with a sustained viral response (SVR) as high as >90%. However, HCV/HIV co-infected individuals have not been able to receive the effective treatment with DAAs due to a number of factors. This paper briefly describes the classification, mechanisms and results of clinical studies on DAAs. In addition, the paper introduces the research on the development of host-targeting agents (HTAs), and treatment of DAAs for HCV/HIV co-infected individuals.
-
Key words:
- Antiviral agents /
- Hepatitis C /
- HIV /
- Therapeutic uses
点击查看大图
计量
- 文章访问数: 375
- HTML全文浏览量: 99
- PDF下载量: 1
- 被引次数: 0